In this study, we found profound tumor cell destruction in CRC cell lines and organoids treated with a combination of T (Torin 1), MK (MK2206) and AZD (selumetinib) or by administration of PKI (gedatolisib) in concert with AZD. Here, PRDX2 is linked to colorectal carcinoma.